Cargando…
Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice
Mycobacterium tuberculosis (Mtb) remains a global health challenge due to the limited efficacy of the Mtb vaccine in current use, Bacillus Calmette–Guérin (BCG). To date, there is no available vaccine for immunocompromised individuals. Thus, there is an urgent need to develop a new vaccine candidate...
Autores principales: | Chuang, Yu-Min, Pinn, Michael L., Karakousis, Petros C., Hung, Chien-Fu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809501/ https://www.ncbi.nlm.nih.gov/pubmed/29473022 http://dx.doi.org/10.3389/fcimb.2018.00031 |
Ejemplares similares
-
DnaK Functions as a Moonlighting Protein on the Surface of Mycoplasma hyorhinis Cells
por: Li, Yao, et al.
Publicado: (2022) -
Targeting the Mycobacterium tuberculosis Stringent Response as a Strategy for Shortening Tuberculosis Treatment
por: Danchik, Carina, et al.
Publicado: (2021) -
Reinkarnál dnak a részecskegyorsít k
Publicado: (2009) -
Albumin fusion with granulocyte-macrophage colony-stimulating factor acts as an immunotherapy against chronic tuberculosis
por: Chuang, Yu-Min, et al.
Publicado: (2020) -
Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?
por: Dutta, Noton K., et al.
Publicado: (2015)